The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heartfailure-related health status (KCCQ) in ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 10.14%, which has investors questioning if this is right time to ...

Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI ...

Investment analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Lexeo Therapeutics in a report ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective dropped by Leerink Partners from $19.00 to $18.00 ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...